Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Global X Genomics & Biotechnology ETF (GNOM)

Global X Genomics & Biotechnology ETF (GNOM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Fund Family Global X Mgt
  • Assets Under Management 17,122,000
  • Market Capitalization, $K 17,122
  • Shares Outstanding, K 1,400
  • 60-Month Beta 3.38
  • Price/Earnings ttm -21.29
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Management Fee 0.68%
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.16 +27.37%
on 03/18/20
14.14 -8.44%
on 03/09/20
-1.61 (-11.06%)
since 03/06/20
3-Month
10.16 +27.37%
on 03/18/20
16.45 -21.33%
on 01/17/20
-2.49 (-16.16%)
since 01/06/20

Most Recent Stories

More News
4 Sector ETFs That Beat the Market in Q4

While Wall Street is surging this quarter, these sector ETFs offered even better performances to beat the market.

DIA : 226.53 (+7.56%)
SOXX : 215.97 (+10.20%)
IEZ : 6.43 (+8.43%)
BBC : 29.74 (+7.52%)
SMH : 123.18 (+9.94%)
PXJ : 1.9100 (+8.71%)
SIL : 25.04 (+5.21%)
XSD : 88.43 (+10.51%)
SBIO : 32.61 (+9.76%)
XPH : 36.35 (+4.42%)
QQQ : 196.48 (+7.15%)
SPY : 264.86 (+6.72%)
GNOM : 12.94 (+5.82%)
SILJ : 7.19 (+8.12%)
Beyond Biotech, 5 ETFs Up At Least 10% in Q4

Apart from biotech, these ETFs are seeing solid momentum in the ongoing quarter.

BBC : 29.74 (+7.52%)
PAK : 5.09 (-1.36%)
SBIO : 32.61 (+9.76%)
JO : 36.65 (+1.44%)
SEA : 8.32 (+0.30%)
UUP : 27.30 (+0.04%)
GNOM : 12.94 (+5.82%)
SILJ : 7.19 (+8.12%)
CHIR : 16.25 (+4.50%)
Biotech Tops in November: Best ETFs & Stocks

The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.

CNCR : 20.23 (+4.11%)
BBC : 29.74 (+7.52%)
BBP : 38.79 (+5.90%)
GBT : 57.40 (+9.00%)
PTI : 1.1600 (+2.65%)
VRTX : 255.30 (+7.13%)
CLVS : 6.80 (+11.48%)
MYOV : 8.56 (+5.94%)
CNST : 31.26 (+3.20%)
KRTX : 69.81 (+12.07%)
CRSP : 42.17 (+7.08%)
ARKG : 31.79 (+6.71%)
GNOM : 12.94 (+5.82%)
Genomics ETFs Surge on CRISPR's Gene Editing Progress

The release of encouraging data on the CRISPR/Cas9 gene-editing therapy CTX001 for two severe blood disorders puts emphasis on some genomic ETFs.

PBE : 47.87 (+5.97%)
VRTX : 255.30 (+7.13%)
CRSP : 42.17 (+7.08%)
ARKG : 31.79 (+6.71%)
IDNA : 27.45 (+4.73%)
GNOM : 12.94 (+5.82%)
Healthcare Sector Outperforming: 5 Best ETFs & Stocks QTD

Healthcare bounced back with an outperformance starting the fourth quarter.

CNCR : 20.23 (+4.11%)
SBIO : 32.61 (+9.76%)
IHF : 164.58 (+7.47%)
BBC : 29.74 (+7.52%)
IRWD : 10.07 (+2.03%)
SEM : 13.32 (+11.00%)
OSMT : 3.13 (+6.46%)
JNCE : 4.96 (+16.43%)
GNOM : 12.94 (+5.82%)
ETFs Poised to Benefit from Gene Editing Revolution

Rising investments and growing technological advancement are favoring the genomic editing space. We take a look at a few ETFs that can cash in on this trend.

AGN : 178.15 (+1.39%)
PBE : 47.87 (+5.97%)
ONCE : 110.05 (-3.10%)
EDIT : 21.35 (+9.15%)
ARKG : 31.79 (+6.71%)
GNOM : 12.94 (+5.82%)
IDNA : 27.45 (+4.73%)
ETFs to Gain From the Booming Genomics Market

Rising investments, surging demand for personalized medicines and shrinking sequencing costs are a slew of factors favouring the genomics space. We look at a few ETFs that can cash in on this trend.

PBE : 47.87 (+5.97%)
ILMN : 278.01 (+5.51%)
IDNA : 27.45 (+4.73%)
GNOM : 12.94 (+5.82%)
ARKG : 31.79 (+6.71%)
Global X Launches GNOM: An ETF targeting the Transformative Genomics Industry

Global X ETFs, the New York-based provider of exchange-traded funds, announced today the launch of the 13th fund in its Thematic Growth suite, the Global X Genomics & Biotechnology ETF (Nasdaq: GNOM)....

GNOM : 12.94 (+5.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Trade GNOM with:

Fund Summary

The Global X Genomics and Biotechnology ETF seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index.

See More

Top 10 Holdings

Name % Holdings
QIAGEN N.V. 6.81%
VERTEX PHARM 6.08%
BIOMARIN PHARMAC 5.97%
ULTRAGENYX PHARM 5.81%
PTC THERAPEUTICS INC 5.68%
ALNYLAM PHARMACE 5.55%
SAREPTA THERAPEUTICS INC 5.46%
AGILENT TECHNOLOGIES INC 4.61%
ILLUMINA INC 4.18%
BLUEPRINT MEDICINES CORP 3.72%

See More

Key Turning Points

2nd Resistance Point 13.15
1st Resistance Point 13.05
Last Price 12.94
1st Support Level 12.73
2nd Support Level 12.53

See More

52-Week High 16.45
Fibonacci 61.8% 14.05
Fibonacci 50% 13.31
Last Price 12.94
Fibonacci 38.2% 12.56
52-Week Low 10.16

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar